#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need accessible, evidence-based education on cannabis dosing and cannabinoid pharmacology to provide informed guidance to patients who are using or considering cannabis products. Training programs that synthesize emerging research help close the gap between retail availability and clinical knowledge, enabling providers to better assess safety, drug interactions, and appropriate recommendations. Patients benefit when their clinicians can discuss cannabinoid effects with accuracy rather than deferring conversations or relying on outdated information.
DeMonet provides specialized cannabis education and consultation services designed to address knowledge gaps among retailers, producers, and healthcare professionals regarding dosing protocols, cannabinoid pharmacology, and recent clinical research. This training initiative is particularly relevant for clinicians who may lack formal education in cannabis therapeutics and need evidence-based guidance to counsel patients effectively. By improving the knowledge base of supply-chain professionals and healthcare providers, the program aims to ensure more consistent, accurate information reaches patients about cannabinoid selection, appropriate dosing, and potential therapeutic applications. Such standardized education becomes increasingly important as cannabis products proliferate in the marketplace and patients seek clinical guidance on their use. Clinicians should consider seeking out or recommending such educational resources to stay current with cannabis pharmacology and to ensure their patients receive scientifically grounded counseling about dosing and product selection.
“After two decades in this field, I can tell you the single biggest barrier to responsible cannabis use isn’t the plant itself, it’s that most dispensary staff and many healthcare providers lack basic pharmacology training, so patients end up making decisions in an information vacuum, which is exactly when harm occurs.”
💊 As cannabis products proliferate with increasingly variable cannabinoid profiles and potencies, healthcare providers face a growing knowledge gap that directly impacts patient safety and counseling quality. Educational initiatives targeting retail and production sectors may help standardize information flow, though the commercial incentives embedded in industry-sponsored training warrant careful scrutiny regarding potential bias in how emerging research is presented. Clinicians should recognize that current cannabis education varies widely in rigor and objectivity, making it essential to critically evaluate any training content and cross-reference recommendations against peer-reviewed literature rather than relying solely on industry resources. Given the ongoing gap between retail product labeling practices and actual cannabinoid content in many jurisdictions, healthcare providers should maintain healthy skepticism about dosing guidance and continue counseling patients on the unpredictability of street and some legal market products. A practical starting point for clinical practice is developing a simple standardized intake question about cannabis use that includes product type and reported potency,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
